ARV-110 free base · Synonyms: Bavdegalutamide

ARV-110 (Bavdegalutamide) is an orally bioavailable, specific androgen receptor (AR) PROTAC degrader that leads to ubiquitination and degradation of…

For research use only. Not for human or veterinary use.

Target PROTACs Androgen Receptor

Research area Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

ARV-110 structure

CAS No.: 2222112-77-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 380.00	BP-01988-1g	In stock	Get quote
5 g	USD 1,180.00	BP-01988-5g	In stock	Get quote
10 g	Inquire	BP-01988-10g	In stock	Inquire

Custom Size Bulk Inquiry

Description

ARV-110 (Bavdegalutamide) is an orally bioavailable, specific androgen receptor (AR) PROTAC degrader that leads to ubiquitination and degradation of AR.

Biological activity

In Vitro Bavdegalutamide completely degrades AR in all cell lines tested, with an observed 50% degradation concentration (DC50) < 1 nM. Bavdegalutamide (0.01 nM-300 nM) leads to AR degradation in LNCaP cells in a dose-dependent manner. Bavdegalutamide (10 nM; 0.5-24 hours) leads to AR degradation in VCaP cells in a time-dependent manner. Bavdegalutamide (10-1000 nM) suppresses the expression of the AR-target gene PSA, inhibits AR-dependent cell proliferation, and induces apoptosis at low nanomolar concentrations. Bavdegalutamide (0.01 nM-100 nM) degrades clinically relevant mutant AR proteins (WT AR, F876L, T877A, M896V and H874V), and retains activity in a high androgen environment (R1881, 100 nM) in VCaP cells. In Vivo Bavdegalutamide (oral gavage; 1 mg/kg; QD) exhibits a greater than 90% AR degradation in vivo. In LNCaP, VCaP and prostate cancer patient derived xenograft (PDX) models, Bavdegalutamide also exhibits significant inhibition of tumor growth and AR signaling. Bavdegalutamide (oral gavage; 3 or 10 mpk; 30 days) demonstrates in vivo efficacy and reduction of AR-target gene expression in a long term, castrate, enzalutamide-resistant VCaP tumor model. The TGI are 70% and 60% for 3 mpk and 10 mpk dosage. Respectively.

Identifiers

SMILES: O=C(C1=NN=C(N2CCC(CN3CCN(C4=CC5=C(C(N(C(CC6)C(NC6=O)=O)C5=O)=O)C=C4F)CC3)CC2)C=C1)N[C@H]7CC[C@H](OC8=CC=C(C#N)C(Cl)=C8)CC7
InChIKey: CLCTZVRHDOAUGJ-SYVGMNBRSA-N

Specifications

MW (average): 812.2880
Formula: C₄₁H₄₃ClFN₉O₆
CAS No.: 2222112-77-6
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, sealed storage, away from moisture; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 26.67 mg/mL

Documents

References

[1]. Neklesa T, et al. ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. Journal of Clinical Oncology. Journal of Clinical Oncology March 1 2019 37(7_suppl):259.

[2]. Zeng S, et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31. PMID: 33160761.

[3]. Wang Y, et al. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020 Feb;10(2):207-238. doi: 10.1016/j.apsb.2019.08.001. Epub 2019 Aug 13. PMID: 32082969; PMCID: PMC7016280.

Same target

Search PROTACs

Same research area

Search Cancer